The overall goal of the Cell Therapies Core (CTC) is to provide service to members to facilitate translation of promising therapies for patients with cancer. The CTC manufactures cellular products in support of novel, investigator-initiated clinical studies, while maintaining compliance with standards set by the U.S. Food and Drug Administration (FDA) and other accrediting bodies. To accomplish this goal, the CTC's Specific Aims are to: 1) Develop new technologies for translation of cellular therapies 2) Provide regulatory assistance in support of cellular therapies 3) Educate and train scientists and clinicians committed to careers in cellular therapies 4) Produce the highest quality cellular products for immunotherapy clinical trials The CTC works with members through all stages of a clinical trial, including collaboration during pre-clinical planning. The CTC technical director, manager, and quality staff assist with preparation of protocols, funding/grant applications, INDs, and other regulatory submissions. Once the cellular therapy agent under study is administered to the patient, the CTC analytic laboratory may continue to assist in post-treatment immune monitoring or, when desired by investigators, may directly conduct the immune monitoring studies. The CTC has four key areas of activity: 1. New product development, wherein new cell therapy products undergo pre-clinical scale-up, testing, and validation 2. Cell collection and cryostorage to obtain mononuclear cells, lymphocytes, and antigen presenting cells for production of cell therapy products and immune monitoring studies 3. Cell therapy product manufacturing, including dendritic and tumor cell-based gene-modified and un- modified vaccines and purification and/or expansion of T lymphocytes (T regulatory cells, tumor infiltrating lymphocytes, tumor antigen-associated T cells, chimeric antigen receptor T cells) 4. An analytic laboratory that performs the dual functions of product quality testing and post-treatment immune monitoring During the project period, the CTC supported 19 cancer center investigators involved in 27 projects and 39 publications. In FY2015, the CTC supported 15 projects, of which 87% represented member projects and 55% of total usage supported peer-review-funded members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-21
Application #
9637347
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
21
Fiscal Year
2019
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Davis, Stacy N; Govindaraju, Swapamthi; Jackson, Brittany et al. (2018) Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry. Nurs Res 67:212-221
Martínez, Úrsula; Brandon, Thomas H; Sutton, Steven K et al. (2018) Associations between the smoking-relatedness of a cancer type, cessation attitudes and beliefs, and future abstinence among recent quitters. Psychooncology 27:2104-2110
Perales-Puchalt, Alfredo; Perez-Sanz, Jairo; Payne, Kyle K et al. (2018) Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 103:799-805
Nelson, Ashley M; Jim, Heather S L; Small, Brent J et al. (2018) Sleep disruption among cancer patients following autologous hematopoietic cell transplantation. Bone Marrow Transplant 53:307-314
Singh, Kshipra; Coburn, Lori A; Asim, Mohammad et al. (2018) Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res 78:4303-4315
Kasting, Monica L; Giuliano, Anna R; Reich, Richard R et al. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. Cancer Epidemiol Biomarkers Prev 27:503-513
Denson, Aaron; Burke, Nancy; Wapinsky, Georgine et al. (2018) Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol 41:133-139
Betts, Brian C; Bastian, David; Iamsawat, Supinya et al. (2018) Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A 115:1582-1587
Pidala, Joseph; Beato, Francisca; Kim, Jongphil et al. (2018) In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica 103:531-539
Hampras, S S; Tommasino, M; Zhao, Y et al. (2018) Cross-sectional associations between cutaneous viral infections and regulatory T lymphocytes in circulation. Br J Dermatol :

Showing the most recent 10 out of 1254 publications